Promising 85% Response: Ru-D Regimen Shows Hope for Adults with HLH
Blood Journals Portfolio recently shared a post on X:
”The Ru-D regimen was well tolerated, resulting in OS rates of 85.7%, 67.9%, and 53.6% at 2 months, 6 months, and 2 years, respectively.”
Read the full article here.
The recently published article ”Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China” by De Zhou et al. in Blood sheds light on the possible positive results from combination of Ruxolitinib with Dexamethasone in HLH patients.
A phase 2 trial of the Ru-D regimen—ruxolitinib combined with dexamethasone—showed promising results in adults newly diagnosed with HLH of unknown triggers.
Among 28 patients, the overall response rate was 85.7%, with a 2-month overall survival rate of 85.7% and favorable 2-year survival in non-lymphoma-associated HLH cases.
The Ru-D regimen was well tolerated, supporting further investigation in a phase 3 trial.
Latest scientific advancements in hematology featured in Hemostasis Today.
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI
-
Nov 8, 2026, 07:16Gilberto de lima Lopes Junior: The Cardiovascular Consequences of Cancer in Younger Patients
-
Nov 8, 2026, 06:51Haney Mallemat: Key Principles and Pitfalls of LVAD Emergencies
-
Nov 8, 2026, 06:31Maria Omer: Clinical Recognition and Management of Cavernous Sinus Thrombosis
-
Nov 8, 2026, 06:16Natasha Jolakoski: University of New Mexico Hospital Promotes PGY-2 Thrombosis and Hemostasis Management Pharmacy Residency
-
Nov 8, 2026, 05:47Safaa Hilal: POCUS in the Evaluation of Perioperative Troponin Elevation